Repatha Insurance Denied? How to Appeal Your Evolocumab PCSK9 Denial

Repatha (evolocumab) is a PCSK9 inhibitor that dramatically lowers LDL cholesterol — often by 60% or more — and has been proven to reduce heart attacks and strokes. Yet it is one of the most commonly denied specialty medications in the United States. If your insurer rejected your Repatha claim, you are far from alone, and you have strong grounds for appeal.

What Repatha Treats and Why Patients Need It

Repatha is a monoclonal antibody that blocks PCSK9, a protein that degrades LDL receptors in the liver. By inhibiting PCSK9, Repatha dramatically reduces LDL cholesterol levels — even in patients on maximally tolerated statin therapy.

Repatha is FDA-approved for:

• Adults with established atherosclerotic cardiovascular disease (ASCVD) to reduce the risk of MI, stroke, and coronary revascularization
• Adults with primary hyperlipidemia (including heterozygous familial hypercholesterolemia) as an adjunct to diet and maximally tolerated statin therapy
• Patients with homozygous familial hypercholesterolemia (HoFH)

In the FOURIER trial, Repatha reduced major cardiovascular events by 15% compared to placebo in patients already on statins. For high-risk cardiovascular patients, this level of additional risk reduction is clinically meaningful.

Common Denial Reasons for Repatha

Step therapy requirements: This is the primary reason for denial. Insurers require patients to demonstrate they are on a statin — typically at maximum tolerated dose — before approving a PCSK9 inhibitor. Many also require a documented trial of ezetimibe (Zetia) before Repatha.

LDL not high enough: Some plans have LDL thresholds (e.g., LDL ≥70 or ≥100 mg/dL on statin therapy) that must be met for Prior Authorization Denied: How to Appeal" class="auto-link">prior authorization approval.

Indication not met: Plans may deny if the documented indication (primary prevention vs. established ASCVD vs. FH) doesn't match their criteria for coverage.

Statin intolerance not adequately documented: If a patient can't tolerate statins and wants Repatha as a replacement, the plan may deny because statin intolerance wasn't adequately documented — requiring documented muscle pain, enzyme elevations, or formal statin intolerance workup.

Formulary exclusion: Some plans prefer Praluent (alirocumab) over Repatha, or exclude PCSK9 inhibitors entirely.

Step-by-Step: How to Appeal a Repatha Denial

Step 1: Get the denial reason in writing. Review the denial letter and EOB closely to identify the exact basis for denial.

Step 2: Confirm your step therapy documentation is complete. Do your records show the statins tried, doses used, duration, and outcomes? Is ezetimibe documented if required? Is statin intolerance formally noted?

Step 3: Get a Letter of Medical Necessity from your cardiologist or lipidologist. The LMN should document: your cardiovascular history, LDL levels on maximally tolerated statin therapy, prior lipid-lowering therapies tried, and the clinical reason Repatha is necessary (ASCVD risk reduction, FH, statin intolerance).

Step 4: Gather labs. Include LDL panels showing current levels on statin therapy. If statin intolerant, include CK levels, ALT/AST elevations, or muscle biopsy documentation if available.

Step 5: File the internal appeal. If denied for step therapy, provide detailed records of all prior treatments. If denied for LDL threshold, document your current LDL levels clearly.

Step 6: Pursue peer-to-peer review. A cardiologist or lipidologist calling the insurance medical director often shifts the outcome significantly.

Step 7: File an external appeal if the internal appeal fails.

What to Include in Your Repatha Appeal Letter

• Patient ID, policy number, claim reference
• Medical history: ASCVD, FH diagnosis, cardiovascular risk factors
• LDL levels: most recent result on current statin therapy (or without statins if intolerant)
• Prior statin therapy: drug names, doses, duration, reason for discontinuation or limitation
• Ezetimibe trial documentation if applicable
• Letter of Medical Necessity from cardiologist or lipid specialist
• FOURIER trial reference for ASCVD indication
• ACC/AHA cholesterol guideline citation supporting PCSK9 inhibitor use in very-high-risk patients
• Request for peer-to-peer review

Success Tips for Repatha Appeals

Document statin intolerance rigorously. If you can't tolerate statins, this is the most powerful argument for Repatha as a first-line agent. Document every statin tried — the dose, duration, reason for stopping (myalgia, myopathy, elevated liver enzymes), and that you rechallenge is not appropriate.

Quantify your cardiovascular risk. The ACC/AHA guidelines support PCSK9 inhibitors for patients with very high cardiovascular risk. Enumerate your risk factors: prior MI, prior stroke, peripheral artery disease, diabetes, hypertension. The more high-risk features you have, the more compelling the case.

Know the FH pathway. Patients with heterozygous or homozygous familial hypercholesterolemia have a stronger coverage argument because FH is a genetic disease causing extreme LDL elevation from birth, and statins alone are often insufficient.

Include LDL before and after statin therapy. Showing LDL levels that remain unacceptably high despite optimized statin use is powerful evidence. A "maximally tolerated statin" argument must be backed by numbers.

Fight Back With ClaimBack

PCSK9 inhibitor denials are common — but they're also commonly reversed on appeal. ClaimBack helps you build a thorough, well-documented appeal to fight for the cholesterol management your heart health demands.

Start your Repatha appeal at ClaimBack

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Common Reasons Insurance Claims Are Denied